Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

ClinicalTrials.gov ID: NCT02014402

Public ClinicalTrials.gov record NCT02014402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This purpose of this clinical trial was to study the safety and efficacy of Topical Thrombin (Human) Grifols as an add-on treatment to help stop bleeding during vascular, liver, soft tissue, and spinal surgical procedures.

Study identification

NCT ID
NCT02014402
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Instituto Grifols, S.A.
Industry
Enrollment
181 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2013 (Type not available)
Primary completion
Nov 2015 (Actual)
Completion
Nov 2015 (Actual)
Last update posted
Jun 14, 2017

2013 – 2015

United States locations

U.S. sites
20
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
805 Tucson Arizona 85712 —
602 Los Angeles California 90048 —
700, 801 Pasadena California 91105 —
803 Boulder Colorado 80303 —
908 Hartford Connecticut 06102 —
601 Washington D.C. District of Columbia 20007 —
507 Gainesville Florida 32611 —
501, 901 Jacksonville Florida 32216 —
604 Evanston Illinois 60208 —
804 Lexington Kentucky 40509 —
905 Baltimore Maryland 21201 —
902 Jackson Mississippi 39216 —
800 Las Vegas Nevada 89144 —
600 New York New York 10029 —
606 Poughkeepsie New York 12601 —
508 Chapel Hill North Carolina 27599 —
503 Fort Worth Texas 76107 —
900 Houston Texas 77024 —
605 Salt Lake City Utah 84132 —
802 Spokane Washington 99208 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02014402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2017 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02014402 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →